Biotechnology

Diakonos Oncology's personalized therapy, DOC1021, reports impressive survival data in early trials for glioblastoma and pancreatic cancer.

Taiwan's SynbioTech is launching a science-backed probiotic portfolio at Vitafoods Europe, targeting a holistic approach to women's active aging.

With CHF 2.5 million in new seed funding, Swiss-based Oberland Biotech is set to tackle the competitive US and Asian nutritional food markets.

A new gene therapy has helped completely blind patients with Retinitis Pigmentosa regain light perception, offering hope to millions with inherited blindness.

Contineum Therapeutics reports encouraging early data for its non-opioid drug PIPE-791, offering a potential new weapon in the fight against chronic pain.

Biotech firm Ocubio adds commercial titan Jim Mazzo and clinical pioneer Dr. Eric Donnenfeld, signaling a major play to disrupt the ocular health market.

VectorBuilder tackles key AAV therapy hurdles in ophthalmology, aiming to boost consistency and unlock new treatments for blinding genetic diseases.

Alkeus Pharmaceuticals will present crucial data on its oral drug for Stargardt disease, a leading cause of juvenile blindness with no current cure.

With fresh capital, the Swedish biotech is scaling its revolutionary platform that decodes cellular communication, fueling a major US expansion.

A Boston biotech is using AI and targeted mRNA to program cells inside the body, aiming to make complex CAR T treatments safer and universally accessible.

As life-saving gene therapies face billion-dollar payment hurdles, a key appointment signals a strategic shift from scientific breakthrough to market access.

New pre-clinical data shows engineered immune cells (iMacrophages) can effectively target and destroy ovarian tumors, offering hope for a new treatment era.

Biotech firm Scribe Therapeutics, co-founded by a Nobel laureate, is pioneering a new gene therapy for high cholesterol that silences genes, not cuts them.

South Korea approves its first homegrown CAR-T therapy, a landmark achievement offering new hope for lymphoma patients with impressive response rates.

New at-home tests for IBS and SIBO are gaining validation, promising faster diagnoses and revealing surprising links between gut health and systemic diseases.

With $5M in new funding and key regulatory validation, Sapho Bio's rapid sterility test promises to slash drug release times and speed medicines to patients.

The clinical trial leader renewed a key global certification, signaling a new era of quality and trust that could accelerate breakthroughs in Alzheimer's.

A new AI platform, SAVA, launched by EverythingALS, promises to connect ALS patients with clinical trials, tackling a major barrier in the search for a cure.

A novel immunotherapy that freezes and infuses tumors shows an 87% response rate in advanced prostate cancer, aiming to turn local treatment into a systemic attack.

As AI accelerates drug approvals, a new bottleneck emerges. Firms like Totaligent are betting on the infrastructure needed to get therapies to patients.